X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1770) 1770
animals (1393) 1393
male (802) 802
dipeptidyl peptidase 4 - metabolism (720) 720
mice (617) 617
female (614) 614
dipeptidyl peptidase 4 - genetics (528) 528
biochemistry & molecular biology (432) 432
diabetes (404) 404
rats (391) 391
endocrinology & metabolism (389) 389
expression (386) 386
type 2 diabetes (354) 354
research (339) 339
diabetes mellitus, type 2 - drug therapy (333) 333
glucagon-like peptide-1 (325) 325
middle aged (307) 307
proteins (307) 307
cell biology (295) 295
dipeptidyl-peptidases and tripeptidyl-peptidases - genetics (295) 295
peptidase (295) 295
dipeptidyl-peptidase iv inhibitors - therapeutic use (287) 287
analysis (284) 284
immunology (283) 283
adult (278) 278
molecular sequence data (275) 275
gene expression (265) 265
dipeptidyl-peptidase iv inhibitors - pharmacology (257) 257
enzymes (256) 256
dipeptidyl-peptidases and tripeptidyl-peptidases - metabolism (252) 252
amino acid sequence (247) 247
glucose (240) 240
research article (232) 232
multidisciplinary sciences (228) 228
cd26 (222) 222
pharmacology & pharmacy (222) 222
peptides (219) 219
diabetes mellitus (214) 214
physiological aspects (213) 213
aged (211) 211
hypoglycemic agents - therapeutic use (211) 211
medicine (211) 211
dipeptidyl peptidase-iv (209) 209
proteases (209) 209
dipeptidyl peptidase 4 (205) 205
mice, inbred c57bl (196) 196
dipeptidyl-peptidase-iv (192) 192
insulin (192) 192
genetic aspects (188) 188
inflammation (183) 183
disease models, animal (178) 178
health aspects (178) 178
sitagliptin (175) 175
cells, cultured (167) 167
dipeptidyl peptidase-4 inhibitor (164) 164
rodents (164) 164
activation (162) 162
cell line (161) 161
glucagon (159) 159
care and treatment (158) 158
medicine, research & experimental (155) 155
dipeptidyl peptidase iv (153) 153
oncology (151) 151
science (151) 151
base sequence (149) 149
inhibition (149) 149
hypoglycemic agents (148) 148
obesity (147) 147
cancer (144) 144
apoptosis (143) 143
mutation (143) 143
inhibitors (142) 142
insulin resistance (139) 139
mice, knockout (135) 135
internal medicine (134) 134
risk factors (133) 133
genetics & heredity (130) 130
protein (130) 130
dipeptidyl peptidase 4 - chemistry (129) 129
cells (128) 128
microbiology (126) 126
studies (125) 125
protein binding (124) 124
physiology (123) 123
medicine & public health (119) 119
dipeptidyl peptidase 4 - blood (118) 118
metabolism (117) 117
signal transduction (117) 117
aminopeptidases - genetics (116) 116
dipeptidyl-peptidases and tripeptidyl-peptidases (116) 116
rna, messenger - metabolism (115) 115
biology (111) 111
neurosciences (111) 111
oxidative stress (111) 111
aminopeptidases (110) 110
drug therapy (110) 110
glp-1 (109) 109
metformin (109) 109
abridged index medicus (108) 108
immunohistochemistry (108) 108
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2752) 2752
Japanese (16) 16
Chinese (4) 4
German (4) 4
Polish (2) 2
Russian (2) 2
Norwegian (1) 1
Portuguese (1) 1
Spanish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Nature immunology, ISSN 1529-2916, 2015, Volume 16, Issue 8, pp. 850 - 858
.... Here we show that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4... 
CD26 EXPRESSION | CELLS | CXCL10 | CHEMOKINE ACTIVITY | IN-VIVO | RECEPTOR | IMMUNOLOGY | CD26/DIPEPTIDYL PEPTIDASE-IV | PROTEINS | CANCER | POSTTRANSLATIONAL MODIFICATION | Dipeptidyl Peptidase 4 - metabolism | Immunotherapy - methods | Male | Adoptive Transfer | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Cell Movement - immunology | Flow Cytometry | Lymphocytes - immunology | Neoplasms, Experimental - immunology | Chemokine CXCL10 - immunology | Neoplasms, Experimental - genetics | Female | Sitagliptin Phosphate | Dipeptidyl Peptidase 4 - immunology | Chemokines - immunology | Lymphocytes - metabolism | Receptors, CXCR3 - metabolism | Mice, Inbred C57BL | Neoplasms, Experimental - therapy | Dipeptidyl Peptidase 4 - genetics | Mice, Transgenic | Mice, Knockout | Triazoles - pharmacology | Cell Movement - drug effects | Animals | Receptors, CXCR3 - immunology | Cell Line, Tumor | Chemokines - metabolism | Mice, Inbred BALB C | Pyrazines - pharmacology | Chemokine CXCL10 - metabolism | Care and treatment | Usage | Immunotherapy | Development and progression | Inflammation | Health aspects | Chemokines | Tumors | Neoplasms, Experimental/genetics | Immunotherapy/methods | Cell Movement/drug effects | Neoplasms, Experimental/therapy | Lymphocytes/metabolism | Lymphocytes/immunology | Dipeptidyl Peptidase 4/genetics | Life Sciences | Chemokine CXCL10/immunology | Immunology | Pyrazines/pharmacology | Dipeptidyl Peptidase 4/immunology | Dipeptidyl-Peptidase IV Inhibitors/pharmacology | Chemokines/metabolism | Receptors, CXCR3/immunology | Receptors, CXCR3/metabolism | Neoplasms, Experimental/immunology | Triazoles/pharmacology | Cell Movement/immunology | Chemokines/immunology | Dipeptidyl Peptidase 4/metabolism | Chemokine CXCL10/metabolism
Journal Article
Clinical and experimental immunology, ISSN 1365-2249, 2016, Volume 184, Issue 3, pp. 265 - 283
Summary Dipeptidyl peptidase (DPP) 4 (CD26, DPP4) is a multi‐functional protein involved in T cell activation by co... 
DPP4 activity and/or structure homologue proteins (DASH) | CD26 | antigen presentation/processing | co‐stimulation | signal transduction | Signal transduction | Antigen presentation/processing | Co-stimulation | IV ACTIVITY | MOLECULAR CHARACTERIZATION | RHEUMATOID-ARTHRITIS | INSULIN-SECRETION | SUBCELLULAR-LOCALIZATION | ENTEROINSULAR AXIS | IMMUNOLOGY | co-stimulation | IMPROVED GLUCOSE-TOLERANCE | NEUROPEPTIDE-Y NPY | SUBSTRATE-SPECIFICITY | FIBROBLAST-ACTIVATION-PROTEIN | Humans | Neoplasms - diagnosis | Caveolin 1 - immunology | Isoenzymes - immunology | Antigen Presentation | Neoplasms - genetics | Serine Endopeptidases - genetics | Serine Endopeptidases - immunology | Cell Differentiation | T-Lymphocytes - pathology | Dipeptidyl Peptidase 4 - immunology | Chemokines - immunology | Gelatinases - immunology | Signal Transduction | Adenosine Deaminase - genetics | Isoenzymes - genetics | Membrane Proteins - genetics | Caveolin 1 - genetics | Dipeptidyl Peptidase 4 - genetics | Gene Expression Regulation, Neoplastic - immunology | Membrane Proteins - immunology | Inflammation | Chemokines - genetics | Gelatinases - genetics | Neoplasms - immunology | T-Lymphocytes - immunology | Biomarkers, Tumor - genetics | Structural Homology, Protein | Neoplasms - pathology | Biomarkers, Tumor - immunology | Adenosine Deaminase - immunology | Proteins | Rodents | antigen presentation | DPP4 activity and | processing | Review | or structure homologue proteins (DASH)
Journal Article
PloS one, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, p. e0133236
...Author(s): Eric G. Meissner [sup.1] [sup.2] [sup.3]*, Jeremie Decalf [sup.4] [sup.5], Armanda Casrouge [sup.4] [sup.5], Henry Masur [sup.3], Shyam Kottilil... 
VIRUS-INFECTION | CHEMOKINES | MULTIDISCIPLINARY SCIENCES | CHRONIC HEPATITIS-C | PROTEIN-10 | GENOTYPE 1 INFECTION | PREDICTIVE-VALUE | RIBAVIRIN | INDUCTION | ASSOCIATION | SPONTANEOUS CLEARANCE | Recurrence | Interferons | Humans | Fluorenes - therapeutic use | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Male | Adult | Female | Hepacivirus - physiology | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Virus Replication - drug effects | Chemokine CXCL10 - blood | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Dipeptidyl Peptidase 4 - genetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Convalescence | Chemokine CXCL10 - genetics | Protein Processing, Post-Translational | Hepatitis C, Chronic - genetics | Viral Load - drug effects | Infection | Care and treatment | Analysis | Interferon | Biological response modifiers | Hepatitis C virus | Health aspects | Therapy | Laboratories | Chronic infection | Critical care | Amino acids | Infections | Ribavirin | Clinical outcomes | Proteins | Genotype & phenotype | Hepatitis | Immunology | Hepatology | Post-translation | Pretreatment | Drug dosages | Genotypes | Statistical analysis | Liver diseases | Dendritic cells | Serum levels | Studies | Infectious diseases | CXCL10 protein | Biomarkers | Chemokines | Virus Replication/drug effects | Viral Load/drug effects | Dipeptidyl Peptidase 4/blood | Dipeptidyl Peptidase 4/genetics | Chemokine CXCL10/blood | Hepatitis C, Chronic/blood | Life Sciences | Hepatitis C, Chronic/drug therapy | Hepatitis C, Chronic/virology | Hepatitis C, Chronic/genetics | Chemokine CXCL10/genetics | Benzimidazoles/therapeutic use | Hepacivirus/physiology | Fluorenes/therapeutic use | Antiviral Agents/therapeutic use | Sofosbuvir/therapeutic use | Hepacivirus/drug effects | Ribavirin/therapeutic use
Journal Article
Virology (New York, N.Y.), ISSN 0042-6822, 2016, Volume 499, pp. 375 - 382
.... It bound strongly to the receptor of MERS-CoV, dipeptidyl peptidase 4 (DPP4), and elicited robust RBD-specific neutralizing antibodies in mice, maintaining long-term neutralizing activity against MERS-CoV infection... 
Infectious Disease | Spike protein | Receptor-binding domain | hDPP4-transgenic mice | Foldon trimerization motif | MERS-CoV | MERS | Protection | Neutralization | ENVELOPE GLYCOPROTEIN TRIMERS | NEUTRALIZING ANTIBODIES | S PROTEIN | BAT CORONAVIRUS | RESPIRATORY SYNDROME CORONAVIRUS | DROMEDARY CAMELS | VIROLOGY | MUCOSAL IMMUNE-RESPONSES | MONOCLONAL-ANTIBODIES | SAUDI-ARABIA | Coronavirus Infections - prevention & control | Spike Glycoprotein, Coronavirus - genetics | Humans | Dipeptidyl Peptidase 4 - genetics | Mice, Transgenic | Receptors, Virus - genetics | Coronavirus Infections - immunology | Middle East Respiratory Syndrome Coronavirus - chemistry | Middle East Respiratory Syndrome Coronavirus - immunology | Antibodies, Neutralizing - immunology | Animals | Coronavirus Infections - virology | Middle East Respiratory Syndrome Coronavirus - genetics | Protein Binding | Protein Domains | Receptors, Virus - immunology | Antibodies, Viral - immunology | Female | Spike Glycoprotein, Coronavirus - immunology | Mice | Mice, Inbred BALB C | Dipeptidyl Peptidase 4 - immunology | Spike Glycoprotein, Coronavirus - chemistry | Coronavirus Infections - enzymology | Viral antibodies | Medical colleges | Biological weapons | Antibodies | Genetic engineering | Blood banks | Biosecurity | Health aspects | Epidemiology | Protein binding | neutralization | spike protein | receptor-binding domain | foldon trimerization motif | protection
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 2011, Volume 124, Issue 21, pp. 2338 - 2349
Background-Dipeptidyl-peptidase 4 (DPP-4) inhibitors are increasingly used to accomplish glycemic targets in patients with type II diabetes mellitus... 
adenosine | atherosclerosis | nitric oxide | diabetes mellitus | monocyte chemoattractant proteins | inflammation | GLYCEMIC CONTROL | CARDIAC & CARDIOVASCULAR SYSTEMS | ADENOSINE-DEAMINASE | DIET-INDUCED OBESITY | GLUCAGON-LIKE PEPTIDE-1 | HUMAN CD26 | INSULIN-RESISTANCE | PERIPHERAL VASCULAR DISEASE | INDEPENDENT PATHWAYS | GLUCOSE-UPTAKE | HEMATOLOGY | TYPE-2 DIABETES-MELLITUS | T-CELLS | Inflammation - pathology | Apolipoproteins E - deficiency | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Male | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Cell Movement - physiology | Uracil - pharmacology | Chemotaxis - physiology | Piperidines - pharmacology | Time Factors | Insulin Resistance - physiology | Metabolism - drug effects | Monocytes - pathology | Receptors, LDL - deficiency | Blood Pressure - drug effects | Disease Models, Animal | Receptors, LDL - genetics | Atherosclerosis - pathology | Atherosclerosis - physiopathology | Uracil - therapeutic use | Chemotaxis - drug effects | Mice, Knockout | Animals | Piperidines - therapeutic use | Apolipoproteins E - genetics | Glucose - metabolism | Inflammation - prevention & control | Mice | Atherosclerosis - prevention & control | Inflammation - physiopathology | Uracil - analogs & derivatives | Care and treatment | Enzyme inhibitors | Research | Proteases | Atherosclerosis
Journal Article
Drug metabolism and disposition, ISSN 0090-9556, 04/2007, Volume 35, Issue 4, pp. 533 - 538
The metabolism and excretion of [C-14] sitagliptin, an orally active, potent and selective dipeptidyl peptidase 4 inhibitor, were investigated in humans after a single oral dose of 83 mg/193 mu Ci... 
DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | DIPEPTIDYL-PEPTIDASE-IV | MK-0431 | SITAGLIPTIN | Cytochrome P-450 CYP2C8 | Triazoles - administration & dosage | Dipeptidyl Peptidase 4 - metabolism | Triazoles - blood | Adenosine Deaminase - metabolism | Area Under Curve | Cytochrome P-450 CYP3A | Enzyme Inhibitors - blood | Humans | Microsomes, Liver - metabolism | Pyrazines - administration & dosage | Aryl Hydrocarbon Hydroxylases - genetics | Glycoproteins - metabolism | Cytochrome P-450 Enzyme System - metabolism | Male | Reference Values | Adenosine Deaminase Inhibitors | Sulfuric Acid Esters - metabolism | Enzyme Inhibitors - administration & dosage | Hypoglycemic Agents - blood | Kidney - metabolism | Glucuronides - metabolism | Enzyme Inhibitors - pharmacokinetics | Hypoglycemic Agents - administration & dosage | Biotransformation | Adult | Triazoles - pharmacokinetics | Molecular Structure | Sitagliptin Phosphate | Enzyme Inhibitors - urine | Triazoles - urine | Recombinant Proteins - metabolism | Hypoglycemic Agents - pharmacokinetics | Hydroxylation | Oxidation-Reduction | Administration, Oral | Glycoproteins - antagonists & inhibitors | Hypoglycemic Agents - urine | Pyrazines - urine | Aryl Hydrocarbon Hydroxylases - metabolism | Feces - chemistry | Cyclization | Pyrazines - pharmacokinetics | Dipeptidyl-Peptidase IV Inhibitors | Cytochrome P-450 Enzyme System - genetics | In Vitro Techniques | Pyrazines - blood | Carbon Radioisotopes
Journal Article
Journal Article
Journal Article
Clinical and experimental immunology, ISSN 0009-9104, 2016, Volume 185, Issue 1, pp. 1 - 21
Journal Article